Johnson & Johnson received U.S. Food and Drug Administration approval for DARZALEX FASPRO® (daratumumab and hyaluronidase‑fihj) in combination with bortezomib, lenalidomide and dexamethasone (D‑VRd) for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
The pivotal Phase 3 CEPHEUS study showed that the D‑VRd regimen achieved a 52.3% overall minimal residual disease (MRD)–negativity rate at a sensitivity of 10‑5, nearly double the 34.8% rate seen with the standard VRd regimen. The study also reported a 40% reduction in the risk of disease progression or death and higher complete response rates of 81.2% versus 61.6% for D‑VRd.
The approval expands Johnson & Johnson’s oncology portfolio with a high‑margin therapy that can generate significant revenue. DARZALEX FASPRO® is already a major driver of the company’s oncology sales, and the new indication adds a foundational treatment for all newly diagnosed patients, regardless of transplant eligibility. The move strengthens J&J’s competitive position in a market where other biologics and small‑molecule agents are intensifying competition and where key patents for drugs such as Stelara and Darzalex are approaching expiration.
CEO Joaquin Duato said the approval “reinforces our commitment to leading the oncology market and delivering innovative therapies that improve patient outcomes.” Duato also highlighted the company’s 2026 revenue guidance of $100 billion to $101 billion, noting that the new indication supports the growth trajectory of the oncology segment, which reported $25.38 billion in sales with a 22.1% year‑over‑year increase.
Analysts reacted positively to the approval, upgrading their outlook for Johnson & Johnson’s oncology business. The market welcomed the expansion of DARZALEX FASPRO® as a high‑margin, high‑penetration therapy that can capture a larger share of the multiple myeloma market and offset upcoming patent expirations.
The FDA approval positions Johnson & Johnson to maintain its leadership in multiple myeloma treatment, providing a robust revenue engine for the oncology portfolio and reinforcing the company’s strategy to become the number one oncology company by 2030.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.